EU/3/15/1570

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.

On 11 November 2015, orphan designation (EU/3/15/1570) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for azacitidine for the treatment of nasopharyngeal carcinoma.

Key facts

Active substance
azacitidine
Disease / condition
Treatment of nasopharyngeal carcinoma
Date of first decision
11/11/2015
Outcome
Withdrawn
EU designation number
EU/3/15/1570

Review of designation

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.

Sponsor's contact details

Celgene Europe Limited
1 Longwalk Road
Stockley Park
Uxbridge
Middlesex UB11 1DB
United Kingdom
Tel. +44 (0)20 8831 8300
Fax +44 (0)20 8831 8301
E-mail: medinfo.uk.ire@celgene.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating